Events
We are very much looking forward to the 2022 edition of the Neuro4D conference, which will take place in Mainz, Germany, on May 16 and 17. Priavoid GmbH will be represented by two speakers. Antje Willuweit will give a talk titled “Development of therapeutic substances for the disassembly of α-synuclein aggregates” at around 5 p.m. on Monday, April 16. Dieter Willbold will be speaking about our Alzheimer’s program PRI-002 on May 17 at around 1:30 p.m. His presentation is titled “PRI-002: towards clinical phase II – preclinical proof of concept and clinical phase I data”
We are looking forward to seeing many more exciting presentations and, of course, to seeing you!
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.